Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104551
Filing Date
2025-08-07
Accepted
2025-08-07 07:07:10
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20250630.htm   iXBRL 10-Q 2114917
2 EX-10.1 cgem-ex10_1.htm EX-10.1 1070945
3 EX-31.1 cgem-ex31_1.htm EX-31.1 15499
4 EX-31.2 cgem-ex31_2.htm EX-31.2 15275
5 EX-32.1 cgem-ex32_1.htm EX-32.1 14312
  Complete submission text file 0000950170-25-104551.txt   9948031

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20250630.xsd EX-101.SCH 1180302
65 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20250630_htm.xml XML 1723509
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 251191547
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)